Comparative Pharmacology
Head-to-head clinical analysis: EVEKEO ODT versus METHAMPHETAMINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EVEKEO ODT versus METHAMPHETAMINE HYDROCHLORIDE.
EVEKEO ODT vs METHAMPHETAMINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EVEKEO ODT (amphetamine) is a CNS stimulant that increases extracellular levels of dopamine and norepinephrine by blocking their reuptake into presynaptic neurons and inhibiting monoamine oxidase, leading to enhanced neurotransmission.
Methamphetamine is a potent central nervous system stimulant that increases synaptic concentrations of dopamine, norepinephrine, and serotonin by reversing their transporters, inhibiting monoamine oxidase, and inhibiting vesicular monoamine transporter 2 (VMAT2).
0.25 mg orally as a single dose; may repeat once after 30 minutes if required.
Oral: 5-10 mg once or twice daily, titrated up to a maximum of 60 mg/day in divided doses. Typical initial dose for ADHD: 5 mg once or twice daily, increase by 5 mg weekly; for obesity: 5 mg before meals, up to 30 mg/day.
None Documented
None Documented
3-5 hours in healthy adults; prolonged in renal impairment (up to 20 hours in ESRD)
Terminal elimination half-life: 10-12 hours. Clinical context: Longer half-life than amphetamine (6-8 h) due to higher lipophilicity and tissue binding. Variability (4–30 h) depends on urine pH, dose, and chronic use (tissue accumulation).
Renal: approximately 50% as unchanged drug and metabolites; fecal: minimal (<10%)
Primarily renal excretion of unchanged drug (30-50%) and metabolites (p-hydroxymethamphetamine, amphetamine, p-hydroxyamphetamine). Up to 70% eliminated over 24 hours. Renal clearance depends on urinary pH; acidic urine (pH <5) increases elimination, alkaline urine reduces it. Biliary/fecal excretion is minimal (<5%).
Category C
Category D/X
CNS Stimulant
CNS Stimulant